Short-Acting Benzodioxole Esters for Lower-Side-Effect Monoamine Release

The patent applies parameter changes by modifying the chemical structure of monoamine releaser compounds, specifically creating short-acting esters with altered pharmacokinetic properties. The ester group modifications (different chain lengths and positions) change the duration of action and potency parameters, allowing effective symptom relief with reduced side effects compared to long-acting compounds like MDMA.

The invention employs short-acting monoamine releaser compounds that produce transient monoamine elevation rather than sustained release. This short-lived pharmacological action mimics the concept of disposable/short-living objects, providing therapeutic benefit for brief periods (hours rather than days) and reducing cumulative side effects and tolerance development.

The patent systematically varies the ester parameters (chain length, position, substitution patterns) to precisely control the duration of monoamine release. By changing these chemical parameters, the compounds achieve optimized half-lives that provide sufficient therapeutic effect without excessive duration, preventing accumulation while maintaining reliability.

The invention creates a dynamic balance in monoamine release by designing compounds with intermediate half-lives. The short-acting nature allows the system to reset between doses, preventing static accumulation while maintaining therapeutic levels during the active period, thus achieving flexibility in dosing and reduced side effects.